Wickersham Karen, Happ Mary Beth, Bender Catherine M
School of Nursing, University of Maryland, Baltimore, 655 West Lombard Street, Room 731A, Baltimore, MD 21201, USA.
Nurs Res Pract. 2012;2012:462121. doi: 10.1155/2012/462121. Epub 2012 Dec 27.
The oral hormonal agent anastrozole improves clinical outcomes for women with breast cancer, but women have difficulty taking it for the five-year course. The unique medication-taking experiences related to self-management of anastrozole therapy for women with early stage breast cancer are not known. Our purpose was to describe the medication-taking experiences for postmenopausal women with early stage breast cancer who were prescribed a course of anastrozole therapy. Twelve women aged 58 to 67 years, midway through therapy, participated in audio-recorded interviews. Women's medication-taking experiences involved a belief in their importance and an imperative to take anastrozole. We found that women's side effect experiences, particularly menopausal symptoms, were significant, but only one woman stopped anastrozole due to side effects. Medication-taking included routinization interconnected with remembering/forgetting and a storage strategy. Some women noted a mutual medication-taking experience with their spouse, but most felt taking anastrozole was something they had to do alone. Our results provide insight into the way some women with early stage breast cancer manage their hormonal therapy at approximately the midpoint of treatment. Next steps should include examinations of patient-provider communication, potential medication-taking differences between pre- and postmenopausal women, and the effects of medication-taking on clinical outcomes.
口服激素药物阿那曲唑可改善乳腺癌女性的临床预后,但女性患者在服用五年疗程药物时存在困难。早期乳腺癌女性在阿那曲唑治疗自我管理方面独特的服药经历尚不清楚。我们的目的是描述接受阿那曲唑疗程治疗的绝经后早期乳腺癌女性的服药经历。12名年龄在58至67岁、处于治疗中期的女性参与了录音访谈。女性的服药经历包括对服药重要性的信念以及服用阿那曲唑的必要性。我们发现,女性的副作用经历,尤其是更年期症状较为明显,但只有一名女性因副作用而停止服用阿那曲唑。服药包括与记忆/遗忘相关的常规化以及一种储存策略。一些女性提到与配偶有共同的服药经历,但大多数人觉得服用阿那曲唑是她们必须独自完成的事情。我们的研究结果为一些早期乳腺癌女性在治疗中期左右如何管理激素治疗提供了见解。接下来的步骤应包括检查医患沟通情况、绝经前和绝经后女性潜在的服药差异以及服药对临床预后的影响。